



FOR IMMEDIATE RELEASE

TRIMGEN CORPORATION SUBMITS 510K TO FDA FOR WARFARIN GENOTYPING KIT

Sparks, Maryland (December 7, 2007) —At the 49th Annual Meeting of the American Society of Hematology, TrimGen Corporation announced the completion of a clinical trial and submission of an application to the FDA for 510K approval for its eQ-PCR™ LightCycler Warfarin Genotyping Kit.

Performed on the Roche LightCycler® platform, TrimGen's eQ-PCR™ LightCycler Warfarin Genotyping Kit is a DNA test that identifies key SNPs in the CYP2C9 and VKORC1 genes. Over 5000 tests were performed during the clinical trial for this product. The results showed 100% agreement between the eQ-PCR™ LightCycler Warfarin system and the corresponding bi-directional sequencing method.

“The clinical trial results for our Warfarin genotyping kit clearly prove the eQ-PCR™ assay's consistent, reliable performance,” commented TrimGen President James Wang. “Our goal with this – and all - our products is to provide better solutions for molecular diagnosis. We are continually looking for ways to improve the diagnostic process, from sample collection to results reporting, and this new assay certainly holds promise for the development of more targeted therapy.”

Warfarin is the most frequently prescribed oral anticoagulant for the treatment and prevention of thromboembolic events. Warfarin, however, is known to cause severe bleeding, a side effect resulting from inter-individual variability in response to the drug. Inter-individual variability is primarily affected by genetic polymorphisms (SNPs) in the VKORC1 (vitamin K epoxide reductase complex subunit 1) and cytochrome P450 CYP2C9 genes. These genetic markers serve as clinically relevant predictors of Warfarin dosing.

The eQ-PCR™ LightCycler Warfarin Genotyping Kit provides accurate patient genetic information that aids in the identification of side-effect risk factors that can be addressed with adjusted dosage, factors which include sensitivity to Warfarin, increased risk for bleeding complications, and inconsistent drug response.

Detailed information about the eQ-PCR™ LightCycler Warfarin Genotyping Kit can be found at www.trimgen.com.

About TrimGen

TrimGen is a diagnostic company focused on developing nucleic acid-based diagnostics products. The Company's proprietary technologies provide high-sensitivity detection methods to pursue early detection of disease-causing genes. The eQ-PCR™ assay, a real-time PCR method, can achieve as low as single-copy detection and the Shifted Termination Assay™, a unique mutation enrichment approach, allows detection as low as 1-2% of somatic mutations. Products in development include assays for leukemia, lymphoma, solid tumor, blood disorder and infectious diseases.

Additional TrimGen products include Mutector™ and Mutector II™ proprietary colorimetric DNA/RNA mutation screening kits, WaxFree™ DNA and BuccalQuick™ kits for PCR-ready DNA from paraffin and buccal samples, and WaxFree™ RNA for RT-ready RNA extraction from paraffin embedded samples.

For additional information regarding this announcement, please contact:

Scott Rediker
TrimGen Corporation
Phone: 410-472-1100
Email: srediker@trimgen.com